Sernova Corp.
TSX:SVA.TOBiotechnology
-$0.01 today
- Market cap
- $50.98M
- Beta
- 0.66
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$0.03
Volume 0.55M
Average 0.12M
SVA.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sernova Corp.TSX: SVA.TO
Research & Development · Q2 FY2026 · quarter ended Apr 2026
Research & development declines year over year
Q2 FY2026 research & development of CA$443.46K fell 81.2% year over year, behind the -73.8% change in trailing-twelve-month research & development. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at -24.5% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -81.2% toward the trailing-twelve-month pace of -73.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 7.28M CAD
- Year-over-year change
- -67.4%
- 4-year CAGR
- +11.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 7.28M | -67.4% |
| FY2024 | 2024-10-31 | 22.36M | -30.7% |
| FY2023 | 2023-10-31 | 32.26M | +90.9% |
| FY2022 | 2022-10-31 | 16.9M | +264.3% |
| FY2021 | 2021-10-31 | 4.64M | — |
Research & Development vs competitors
How SVA.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -73.8% is the lowest of 2, against a peer median of +39.4%.
- Over three fiscal years its annual growth of -24.5% compares with a peer median of +39.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $25.8M USD | +39.4% | +39.0% | — | |
| LTM Apr 2026 | CA$3.33M CAD | -73.8% | -24.5% | — | |
| Peer median (excluding SVA.TO) | — | +39.4% | +39.0% | — | |
Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 267.2K | 440K | 445.55K | 540.28K | 342.59K |
| Gross Profit | (267.2K) | (440K) | (445.55K) | (540.28K) | (342.59K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 4.64M | 16.9M | 32.26M | 22.36M | 7.28M |
| Selling, General & Admin | 2.29M | 7.83M | 8.46M | 8.97M | 7.5M |
| Operating Expenses | 6.94M | 24.75M | 41.13M | 31.84M | 14.78M |
| Depreciation & Amortization | 267.2K | 440K | 308.49K | 410.53K | 342.59K |
| EBITDA | (6.6M) | (24.54M) | (40.19M) | (31.25M) | (14.74M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.87M) | (24.18M) | (41.13M) | (31.84M) | (15.12M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 70.55K | 577.29K | 1.5M | 388.39K | 25.63K |
| Interest Expense | 58.37K | 118K | 32.08K | 586.86K | 754.81K |
| Other Income / Expenses | 1.09M | 1.01M | 1.5M | (347.04K) | (711.01K) |
| Income Before Tax | (6.97M) | (24.42M) | (39.63M) | (32.19M) | (15.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 58.37K | 118K | (629.02K) | 7K | (92.19K) |
| Net Income | (7.02M) | (24.54M) | (39M) | (32.19M) | (15.74M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.03) | (0.09) | (0.13) | (0.10) | (0.05) |
| EPS (Diluted) | (0.03) | (0.09) | (0.13) | (0.10) | (0.05) |
| Weighted Avg Shares | 245.52M | 273.59M | 303.33M | 306.96M | 328.29M |
| Weighted Avg Shares (Diluted) | 245.52M | 273.59M | 303.33M | 306.95M | 328.29M |
Sernova Corp.
TSX:SVA.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.